Neutralizing antibodies to 500 microg interferon beta-1b: 28-month results of the IDEAS extension trial.
The Interferon Dose Escalation Assessment of Safety extension trial monitored neutralizing antibodies to interferon beta-1b in patients who currently or had previously received the double dose (500 microg) for up to 28 months. Fifteen patients entered the extension trial; five patients were neutralizing antibody-positive at the start of the trial. The present study demonstrates that when neutralizing antibodies develop in patients receiving higher doses of interferon beta-1b they tend to persist for a prolonged period, although neutralizing antibody titers tend to decrease over time and some patients may revert to neutralizing antibody-negative status.
Gottesman
M H
MH
Winthrop University Hospital, Mineola, New York 11501, USA. mgottes@winthrop.org
Friedman-Urevich
S
S
Boylan
E
E
Cheng
D
D
D000328:Adult; D019138:Antibodies, Blocking / Q000032:analysis*; D004185:Disability Evaluation; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D009500:Neutralization Tests; D010352:Patient Dropouts; D016896:Treatment Outcome
D019138:Antibodies, Blocking; D000068576:Interferon beta-1b; D016899:Interferon-beta